1
|
Ingram N, McVeigh LE, Abou-Saleh RH, Batchelor DVB, Loadman PM, McLaughlan JR, Markham AF, Evans SD, Coletta PL. A Single Short 'Tone Burst' Results in Optimal Drug Delivery to Tumours Using Ultrasound-Triggered Therapeutic Microbubbles. Pharmaceutics 2022; 14:pharmaceutics14030622. [PMID: 35335995 PMCID: PMC8953493 DOI: 10.3390/pharmaceutics14030622] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/31/2022] [Revised: 03/04/2022] [Accepted: 03/09/2022] [Indexed: 12/10/2022] Open
Abstract
Advanced drug delivery systems, such as ultrasound-mediated drug delivery, show great promise for increasing the therapeutic index. Improvements in delivery by altering the ultrasound parameters have been studied heavily in vitro but relatively little in vivo. Here, the same therapeutic microbubble and tumour type are used to determine whether altering ultrasound parameters can improve drug delivery. Liposomes were loaded with SN38 and attached via avidin: biotin linkages to microbubbles. The whole structure was targeted to the tumour vasculature by the addition of anti-vascular endothelial growth factor receptor 2 antibodies. Tumour drug delivery and metabolism were quantified in SW480 xenografts after application of an ultrasound trigger to the tumour region. Increasing the trigger duration from 5 s to 2 min or increasing the number of 5 s triggers did not improve drug delivery, nor did changing to a chirp trigger designed to stimulate a greater proportion of the microbubble population, although this did show that the short tone trigger resulted in greater release of free SN38. Examination of ultrasound triggers in vivo to improve drug delivery is justified as there are multiple mechanisms at play that may not allow direct translation from in vitro findings. In this setting, a short tone burst gives the best ultrasound parameters for tumoural drug delivery.
Collapse
Affiliation(s)
- Nicola Ingram
- Leeds Institute of Medical Research, Faculty of Medicine and Health, St James’s University Hospital, Beckett Street, Leeds LS9 7TF, UK; (L.E.M.); (J.R.M.); (A.F.M.)
- Correspondence: (N.I.); (P.L.C.)
| | - Laura E. McVeigh
- Leeds Institute of Medical Research, Faculty of Medicine and Health, St James’s University Hospital, Beckett Street, Leeds LS9 7TF, UK; (L.E.M.); (J.R.M.); (A.F.M.)
| | - Radwa H. Abou-Saleh
- School of Physics and Astronomy, University of Leeds, Leeds LS2 9JT, UK; (R.H.A.-S.); (D.V.B.B.); (S.D.E.)
- Nanoscience and Technology Group, Faculty of Science, Galala University, Galala 43711, Egypt
- Department of Physics, Mansoura University, Mansoura 35516, Egypt
| | - Damien V. B. Batchelor
- School of Physics and Astronomy, University of Leeds, Leeds LS2 9JT, UK; (R.H.A.-S.); (D.V.B.B.); (S.D.E.)
| | - Paul M. Loadman
- Institute of Cancer Therapeutics, University of Bradford, Bradford BD7 1DP, UK;
| | - James R. McLaughlan
- Leeds Institute of Medical Research, Faculty of Medicine and Health, St James’s University Hospital, Beckett Street, Leeds LS9 7TF, UK; (L.E.M.); (J.R.M.); (A.F.M.)
- School of Electronic and Electrical Engineering, University of Leeds, Leeds LS2 9JT, UK
| | - Alexander F. Markham
- Leeds Institute of Medical Research, Faculty of Medicine and Health, St James’s University Hospital, Beckett Street, Leeds LS9 7TF, UK; (L.E.M.); (J.R.M.); (A.F.M.)
| | - Stephen D. Evans
- School of Physics and Astronomy, University of Leeds, Leeds LS2 9JT, UK; (R.H.A.-S.); (D.V.B.B.); (S.D.E.)
| | - P. Louise Coletta
- Leeds Institute of Medical Research, Faculty of Medicine and Health, St James’s University Hospital, Beckett Street, Leeds LS9 7TF, UK; (L.E.M.); (J.R.M.); (A.F.M.)
- Correspondence: (N.I.); (P.L.C.)
| |
Collapse
|
2
|
Pramanik A, Xu Z, Shamsuddin SH, Khaled YS, Ingram N, Maisey T, Tomlinson D, Coletta PL, Jayne D, Hughes TA, Tyler AII, Millner PA. Affimer Tagged Cubosomes: Targeting of Carcinoembryonic Antigen Expressing Colorectal Cancer Cells Using In Vitro and In Vivo Models. ACS APPLIED MATERIALS & INTERFACES 2022; 14:11078-11091. [PMID: 35196008 PMCID: PMC9007418 DOI: 10.1021/acsami.1c21655] [Citation(s) in RCA: 34] [Impact Index Per Article: 17.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 11/08/2021] [Accepted: 02/17/2022] [Indexed: 05/10/2023]
Abstract
Nanomedicines, while having been approved for cancer therapy, present many challenges such as low stability, rapid clearance, and nonspecificity leading to off-target toxicity. Cubosomes are porous lyotropic liquid crystalline nanoparticles that have shown great premise as drug delivery vehicles; however, their behavior in vivo is largely underexplored, hindering clinical translation. Here, we have engineered cubosomes based on the space group Im3m that are loaded with copper acetylacetonate as a model drug, and their surfaces are functionalized for the first time with Affimer proteins via copper-free click chemistry to actively target overexpressed carcinoembryonic antigens on LS174T colorectal cancer cells. Unlike nontargeted cubosomes, Affimer tagged cubosomes showed preferential accumulation in cancer cells compared to normal cells not only in vitro (2D monolayer cell culture and 3D spheroid models) but also in vivo in colorectal cancer mouse xenografts, while exhibiting low nonspecific absorption and toxicity in other vital organs. Cancerous spheroids had maximum cell death compared to noncancerous cells upon targeted delivery. Xenografts subjected to targeted drug-loaded cubosomes showed a 5-7-fold higher drug accumulation in the tumor tissue compared to the liver, kidneys, and other vital organs, a significant decrease in tumor growth, and an increased survival rate compared to the nontargeted group. This work encompasses the first thorough preclinical investigation of Affimer targeted cubosomes as a cancer therapeutic.
Collapse
Affiliation(s)
- Arindam Pramanik
- School
of Biomedical Sciences, University of Leeds, Leeds LS2 9JT, United Kingdom
- School
of Medicine, University of Leeds, Leeds LS9 7TF, United Kingdom
| | - Zexi Xu
- School
of Food Science and Nutrition, University
of Leeds, Leeds LS2 9JT, United Kingdom
- School
of Chemistry and Astbury Centre for Structural Molecular Biology, University of Leeds, Leeds LS2 9JT, United Kingdom
| | - Shazana H. Shamsuddin
- School
of Biomedical Sciences, University of Leeds, Leeds LS2 9JT, United Kingdom
- Department
of Pathology, School of Medical Sciences, Universiti Sains Malaysia, George Town 16150, Malaysia
| | - Yazan S. Khaled
- School
of Medicine, University of Leeds, Leeds LS9 7TF, United Kingdom
| | - Nicola Ingram
- Leeds Institute
of Medical Research, St James’s University
Hospital, Leeds LS9 7TF, United Kingdom
| | - Thomas Maisey
- School
of Medicine, University of Leeds, Leeds LS9 7TF, United Kingdom
| | - Darren Tomlinson
- Biomedical
Health Research Centre, BioScreening Technology Group, University of Leeds, Leeds LS2 9JT, United Kingdom
| | - P. Louise Coletta
- Leeds Institute
of Medical Research, St James’s University
Hospital, Leeds LS9 7TF, United Kingdom
| | - David Jayne
- Leeds Institute
of Medical Research, St James’s University
Hospital, Leeds LS9 7TF, United Kingdom
| | - Thomas A. Hughes
- School
of Medicine, University of Leeds, Leeds LS9 7TF, United Kingdom
| | - Arwen I. I. Tyler
- School
of Food Science and Nutrition, University
of Leeds, Leeds LS2 9JT, United Kingdom
| | - Paul A. Millner
- School
of Biomedical Sciences, University of Leeds, Leeds LS2 9JT, United Kingdom
| |
Collapse
|
3
|
Ho YJ, Huang CC, Fan CH, Liu HL, Yeh CK. Ultrasonic technologies in imaging and drug delivery. Cell Mol Life Sci 2021; 78:6119-6141. [PMID: 34297166 PMCID: PMC11072106 DOI: 10.1007/s00018-021-03904-9] [Citation(s) in RCA: 12] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/09/2021] [Revised: 07/13/2021] [Accepted: 07/19/2021] [Indexed: 12/14/2022]
Abstract
Ultrasonic technologies show great promise for diagnostic imaging and drug delivery in theranostic applications. The development of functional and molecular ultrasound imaging is based on the technical breakthrough of high frame-rate ultrasound. The evolution of shear wave elastography, high-frequency ultrasound imaging, ultrasound contrast imaging, and super-resolution blood flow imaging are described in this review. Recently, the therapeutic potential of the interaction of ultrasound with microbubble cavitation or droplet vaporization has become recognized. Microbubbles and phase-change droplets not only provide effective contrast media, but also show great therapeutic potential. Interaction with ultrasound induces unique and distinguishable biophysical features in microbubbles and droplets that promote drug loading and delivery. In particular, this approach demonstrates potential for central nervous system applications. Here, we systemically review the technological developments of theranostic ultrasound including novel ultrasound imaging techniques, the synergetic use of ultrasound with microbubbles and droplets, and microbubble/droplet drug-loading strategies for anticancer applications and disease modulation. These advancements have transformed ultrasound from a purely diagnostic utility into a promising theranostic tool.
Collapse
Affiliation(s)
- Yi-Ju Ho
- Department of Biomedical Engineering and Environmental Sciences, National Tsing Hua University, Hsinchu, Taiwan
| | - Chih-Chung Huang
- Department of Biomedical Engineering, National Cheng Kung University, Tainan, Taiwan
- Medical Device Innovation Center, National Cheng Kung University, Tainan, Taiwan
| | - Ching-Hsiang Fan
- Department of Biomedical Engineering, National Cheng Kung University, Tainan, Taiwan
- Medical Device Innovation Center, National Cheng Kung University, Tainan, Taiwan
| | - Hao-Li Liu
- Department of Electrical Engineering, National Taiwan University, Taipei, Taiwan.
| | - Chih-Kuang Yeh
- Department of Biomedical Engineering and Environmental Sciences, National Tsing Hua University, Hsinchu, Taiwan.
| |
Collapse
|
4
|
McVeigh LE, Wijetunga I, Ingram N, Marston G, Prasad R, Markham AF, Coletta PL. Development of orthotopic tumour models using ultrasound-guided intrahepatic injection. Sci Rep 2019; 9:9904. [PMID: 31289364 PMCID: PMC6616610 DOI: 10.1038/s41598-019-46410-6] [Citation(s) in RCA: 17] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/28/2019] [Accepted: 06/25/2019] [Indexed: 01/19/2023] Open
Abstract
Mouse models of human diseases are an essential part of the translational pipeline. Orthotopic tumour mouse models are increasingly being used in cancer research due to their increased clinical relevance over subcutaneous xenograft models, particularly in relation to metastatic disease. In this study, we have developed orthotopic colorectal cancer liver metastases (CRCLM) and primary cholangiocarcinoma (CCA) models in BALB/c nude mice using minimally invasive ultrasound-guided intrahepatic injection. Due to its minimally invasive nature, the method reduced risk from surgical complications whilst being fast and easy to perform and resulted in measurable tumour volumes 1 to 3 weeks post-injection. Tumour volumes were monitored in vivo by weekly high-frequency ultrasound (HF-US) and/or twice weekly bioluminescence imaging (BLI) and confirmed with end-point histology. Take rates were high for human CRC cells (>73%) and for CCA cells (90%). We have demonstrated that this method reliably induces CRCLM and CCAs, in which tumour volume can be monitored throughout using HF-US and/or BLI. This provides a promising experimental tool for future testing of cancer therapeutics in an orthotopic model.
Collapse
Affiliation(s)
- L E McVeigh
- Leeds Institute of Medical Research, St James's University Hospital, Leeds, LS9 7TF, UK.
| | - I Wijetunga
- Leeds Institute of Medical Research, St James's University Hospital, Leeds, LS9 7TF, UK
| | - N Ingram
- Leeds Institute of Medical Research, St James's University Hospital, Leeds, LS9 7TF, UK
| | - G Marston
- Leeds Institute of Medical Research, St James's University Hospital, Leeds, LS9 7TF, UK
| | - R Prasad
- Department of Hepatobiliary and Transplant Surgery, St. James's University Hospital, Leeds, LS9 7TF, UK
| | - A F Markham
- Leeds Institute of Medical Research, St James's University Hospital, Leeds, LS9 7TF, UK
| | - P L Coletta
- Leeds Institute of Medical Research, St James's University Hospital, Leeds, LS9 7TF, UK
| |
Collapse
|
5
|
Grover SP, Evans CE, Patel AS, Modarai B, Saha P, Smith A. Assessment of Venous Thrombosis in Animal Models. Arterioscler Thromb Vasc Biol 2015; 36:245-52. [PMID: 26681755 DOI: 10.1161/atvbaha.115.306255] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/05/2015] [Accepted: 11/30/2015] [Indexed: 12/19/2022]
Abstract
Deep vein thrombosis and common complications, including pulmonary embolism and post-thrombotic syndrome, represent a major source of morbidity and mortality worldwide. Experimental models of venous thrombosis have provided considerable insight into the cellular and molecular mechanisms that regulate thrombus formation and subsequent resolution. Here, we critically appraise the ex vivo and in vivo techniques used to assess venous thrombosis in these models. Particular attention is paid to imaging modalities, including magnetic resonance imaging, micro-computed tomography, and high-frequency ultrasound that facilitate longitudinal assessment of thrombus size and composition.
Collapse
Affiliation(s)
- Steven P Grover
- From the Cardiovascular Division, Academic Department of Vascular Surgery, Kings College London, BHF Centre of Research Excellence and NIHR Biomedical Research Centre at Kings Health Partners, St Thomas' Hospital, London, United Kingdom
| | - Colin E Evans
- From the Cardiovascular Division, Academic Department of Vascular Surgery, Kings College London, BHF Centre of Research Excellence and NIHR Biomedical Research Centre at Kings Health Partners, St Thomas' Hospital, London, United Kingdom
| | - Ashish S Patel
- From the Cardiovascular Division, Academic Department of Vascular Surgery, Kings College London, BHF Centre of Research Excellence and NIHR Biomedical Research Centre at Kings Health Partners, St Thomas' Hospital, London, United Kingdom
| | - Bijan Modarai
- From the Cardiovascular Division, Academic Department of Vascular Surgery, Kings College London, BHF Centre of Research Excellence and NIHR Biomedical Research Centre at Kings Health Partners, St Thomas' Hospital, London, United Kingdom
| | - Prakash Saha
- From the Cardiovascular Division, Academic Department of Vascular Surgery, Kings College London, BHF Centre of Research Excellence and NIHR Biomedical Research Centre at Kings Health Partners, St Thomas' Hospital, London, United Kingdom.
| | - Alberto Smith
- From the Cardiovascular Division, Academic Department of Vascular Surgery, Kings College London, BHF Centre of Research Excellence and NIHR Biomedical Research Centre at Kings Health Partners, St Thomas' Hospital, London, United Kingdom
| |
Collapse
|